Dr. Philipp Hoffmann
Director, Business Development
Daiichi Sankyo/U3 Pharma: development of innovative cancer therapies.
The biotech company U3 Pharma, which belongs to Daiichi Sankyo since 2008, is a source of several new oncology compounds for the Japanese mother company. Most advanced is U3-1287, a anti-HER3 antibody. That could lead to a new cancer drug with high benefits for the patients. With its innovative research and development U3 Pharma contributes to the goal of Daiichi Sankyo to build up a top-ten oncology pipeline till 2015.